Get started
Keyword

BCR-ABL

Description: An oncogenic fusion gene formed when parts of the BCR and ABL1 genes join, associated especially with chronic myeloid leukemia and some acute leukemias.
Wikidata ID: wiki/Q27653851
OpenAlex ID: keywords/bcr-abl
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
1996 · Brian J. Druker, Shu Tamura, et al. · Nature Medicine · 3,644
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
2001 · Mercedes E. Gorre, Mansoor Mohammed, et al. · Science · 3,102
MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens
2014 · Wei Li, Han Xu, et al. · Genome biology · 2,666
PDF
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
2006 · James A. McCubrey, Linda S. Steelman, et al. · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · 2,285
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling
2002 · Eng-Juh Yeoh, Mary E Ross, et al. · Cancer Cell · 1,917
PDF
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
2002 · Neil P. Shah, John M. Nicoll, et al. · Cancer Cell · 1,612
PDF
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
2010 · François-Xavier Mahon, Delphine Réa, et al. · The Lancet Oncology · 1,550
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
2005 · Ellen Weisberg, Paul W. Manley, et al. · Cancer Cell · 1,492
PDF
Granulocyte–Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML
2004 · Catriona H.M. Jamieson, Laurie E. Ailles, et al. · New England Journal of Medicine · 1,487
PDF
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
2002 · Renaud Capdeville, Elisabeth Buchdunger, et al. · Nature Reviews Drug Discovery · 1,389
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
1990 · Tracy G. Lugo, Ann-Marie Pendergast, et al. · Science · 1,281
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
2001 · Allan T van Oosterom, Ian Judson, et al. · The Lancet · 1,264
Protein Kinase Inhibitors: Insights into Drug Design from Structure
2004 · Martin E. M. Noble, Jane A. Endicott, et al. · Science · 1,200
Tracking cancer drugs in living cells by thermal profiling of the proteome
2014 · Mikhail M. Savitski, Mikhail M. Savitski, et al. · Science · 1,171
Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease
1999 · JJM van Dongen, EA Macintyre, et al. · Leukemia · 1,169
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
2006 · Risto Kerkelä, Luanda Grazette, et al. · Nature Medicine · 1,159
Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate
2006 · Dunyaporn Trachootham, Yan Zhou, et al. · Cancer Cell · 1,078
PDF
Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia
2005 · Ruibao Ren · Nature reviews. Cancer · 1,057
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
2002 · Ralf Buettner, Linda B Mora, et al. · PubMed · 1,024
Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
2003 · John M. Goldman, Junia V. Melo · New England Journal of Medicine · 951
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
2002 · Bhushan Nagar, William G Bornmann, et al. · PubMed · 928
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
2016 · A Hochhaus, G Saglio, et al. · Leukemia · 839
PDF
Dynamics of chronic myeloid leukaemia
2005 · Franziska Michor, Timothy P. Hughes, et al. · Nature · 833
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance
2000 · François Xavier Mahon, Michael W. N. Deininger, et al. · Blood · 775
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
2010 · Amie S. Corbin, Anupriya Agarwal, et al. · Journal of Clinical Investigation · 766
Works count: 13,570
Citation count: 284,300
Year
Topic
Type